PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening

Human epidermal growth factor receptor (EGFR) 2 (HER2) is overexpressed/amplified in about 25% of all breast cancers, and EGFR is overexpressed in up to 76% and amplified in up to 24% of triple-negative breast cancers (TNBC). Here, we aimed to identify inhibitors that may enhance the anti-tumor acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jangsoon, Liu, Huey, Pearson, Troy, Iwase, Toshiaki, Fuson, Jon, Lalani, Alshad S., Eli, Lisa D., Diala, Irmina, Tripathy, Debu, Lim, Bora, Ueno, Naoto T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301343/
https://www.ncbi.nlm.nih.gov/pubmed/34203351
http://dx.doi.org/10.3390/biomedicines9070740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301343/
https://www.ncbi.nlm.nih.gov/pubmed/34203351
http://dx.doi.org/10.3390/biomedicines9070740

Ejemplares similares